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Hepatocellular carcinomas with a high proliferation index and a low degree
of apoptosis and necrosis are associated with a shortened survival
Y Soini, N Virkajarvi, V-P Lehto and P Paakko
Departments ofPathology, University of Oulu and Oulu University Central Hospital, Oulu, Finland.
Summary In this study we investigated tumour growth in relation to the immunohistochemical expression of
p53 and bcl-2 and to patient survival data in 33 operated hepatocellular carcinomas (HCCs). In order to
estimate the growth, a growth index, based on the degree of cell proliferation, apoptosis and necrosis, was
calculated for each tumour. Cell proliferation was determined immunohistochemically by the number of
proliferating cell nuclear antigen (PCNA)-positive cells in tumours, the extent of apoptosis was determined by
counting the number of cells labelled by the in situ 3'-end labelling technique and tumour necrosis was
estimated as the percentage of necrotic areas in haematoxylin-eosin-stained tissue sections. In our analysis we
found that the survival of patients with HCCs showing a high growth index (i.e. tumours showing a high
proliferation and simultaneously a low degree of apoptosis and necrosis) was significantly shorter than with
other patients (P=0.004, log-rank test). When analysed separately, cell proliferation, apoptosis or necrosis did
not show any significant association with survival. p53 positivity was found in 8/33 (24%) of tumours. There
were significantly more p53-positive cases in tumours with a high growth index (P=0.01, Fisher's exact test)
suggesting that dysfunction of the p53 gene may affect tumour growth. p53-positive cases did not, however,
have a significantly shorter survival time than p53-negative cases (P=0.3, log-rank test). bcl-2 positivity was
found in only 1/33 (3%) of the HCCs. Thus bcl-2 overexpression does not seem to play an important role in
hepatocellular carcinogenesis. In summary, our results suggest that in HCCs a compound score based on the
evaluation of the degree of cell proliferation, apoptosis and necrosis is a biologically more relevant prognostic
indicator than any of its composite parameters alone.
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The growth of a tumour depends on the proliferative capacity
and destruction of the tumour cells (Reed, 1994). Destruction
of tumour cells can take place via apoptosis or necrosis.
Characteristically, apoptosis is a biochemically highly regu-
lated cell death that is often triggered by intrinsic mechanisms
of the cell and typically involves scattered cells. Necrotic cell
death, on the other hand, is due to environmental factors, such
as loss of blood supply, which leads to a mass destruction of
cells within a certain tumour area.
Apoptosis is regulated by several oncogenes and tumour-
suppressor genes. An important group of genes regulating
apoptosis are the bcl-2 gene family which includes bcl-2, bax,
bcl-xL, bcl-xS, mcl-I and bad (Hockenberry, 1994; Reed,
1994). They can either inhibit or promote apoptosis. bcl-2,
for instance, inhibits while bax promotes apoptosis
(Hockenberry, 1994; Reed, 1994; Miyashita and Reed,
1995). Translocation of the bcl-2 gene in follicular
lymphomas leads to an overexpression of bcl-2 protein and
a decreased apoptosis (Tsujimoto et al., 1985).
p53 is a tumour-suppressor gene that participates in DNA
repair following DNA damage (Lane, 1992). Upon DNA
damage, p53 protein accumulates in the nucleus leading to a
halt of the cell cycle at the G,-S boundary, which gives time
for DNA repair to occur (Lane, 1992). If the DNA repair
fails, p53 will trigger apoptosis (Lane, 1992; Younish-Rouach
et al., 1991). Mutation of the p53 gene leads to loss of
function which, in turn, leads to a genetic instability and
neoplastic transformation (Lane, 1992).
Mutations of the p53 gene are found in 38% of human
malignant tumours (Greenblatt et al., 1994). In hepatocellular
carcinoma (HCC) p53 mutations are found in 25-50% of
cases (Greenblatt et al., 1994). There is a wide geographical
variation in the incidence of p53 mutations in HCC that
depend on the presence or absence of two major risk factors;
dietary aflatoxin and hepatitis B and C infections (Greenblatt
et al., 1994; Wands and Blum, 1991). In Europe and North
America, where both of these risk factors are low or non-
existent, the incidence of HCC is lower and p53 mutations in
liver cancer occurs only in 10-25% of HCCs (Greenblatt et
al., 1994; Volkmann et al., 1994).
Morphological analysis of the degree and pattern of
apoptosis and its relation to p53 expression and survival
data in HCC has not so far been performed. In this study, we
analysed the proliferative activity, apoptosis and necrosis in
33 HCCs removed at surgery and correlated the data with
immunohistochemical expression of p53, bcl-2 and clinical
data including, for example, survival of the patients. In order
to estimate the net growth of the tumours, the proliferative
activity, apoptosis and necrosis were scored separately and
then combined to a single index that was compared with the
other known parameters of the cases.
Materials and methods
Materials
A total of 33 HCCs from the years 1983-93 were collected
from the files of the Department of Pathology, Oulu
University Central Hospital. The diagnosis of all cases was
based on a conventional light microscopy according to the
criteria of the World Health Organization (Gibson and
Sobin, 1978). A predominantly compact histological pattern
was seen in 19, trabecular in 11, acinar in two and
fibrolamellar in one HCC. One of the tumours was of grade
IV, 15 of grade III, 15 of grade II and two of grade I
(Edmondson and Steiner, 1954). In all cases, a complete
surgical resection of the tumour was performed. The case
histories of all the patients were reviewed and the pertinent
clinical data, including the survival, stage (Spiessl et al.,
1992), age and sex of the patients were collected. Six of the
patients were alive, five had died of other disease or during
the operation. A total 14 patients received chemotherapy
(mitomycin, epirubicin, doxorubicin) following surgery. One
patient had a history of viral hepatitis, two patients had
Correspondence: Y Soini, Department of Pathology, University of
Oulu, Kajaanintie 52 D, FIN-90220 Oulu, Finland
Received 1 September 1995; revised 27 November 1995; accepted 30
November 1995PCNA, apoptosis and necrosis in hepatocellular carcinoma
Y Soini et al
1026
chronic aggressive hepatitis and one had primary biliary
cirrhosis. Seven of the patients had cirrhosis. The average age
of the patients was 60.9+15.5 years and the average size of
the tumours 10.8+7.2 cm. There were 14 males and 19
females in the study.
Immunohistochemical stainings
Sections (5 giM) were cut from the specimens and placed on
poly-L-lysine-coated (Sigma Chemicals, St Louis, MO, USA)
glass slides, air-dried overnight and stained within a few days.
The sections (one representative section per case) were then
dewaxed in xylene and rehydrated in graded alcohol. The
endogenous peroxidase was consumed by immersing the
sections in 0.1% hydrogen peroxide in absolute methanol for
20 min. Non-specific binding was blocked by incubating the
slides in 20% fetal calf serum in phosphate-buffered saline
(PBS) for 20 min.
A monoclonal antibody (clone 124) against bcl-2
oncoprotein was obtained from Dako (Glostrup, Denmark).
Before application of the primary antibody, the sections were
heated in a microwave oven in 10 mM citric acid mono-
hydrate, pH 6.0, for 3 min. After a 30 min incubation with
the primary antibody (dilution 1:50), a biotinylated secondary
anti-mouse antibody (Dakopatts, Copenhagen, Denmark)
was applied (dilution 1:300) followed by the avidin-
biotin-peroxidase complex (Dakopatts).
For p53 staining, the sections were first incubated
overnight at 4°C with a polyclonal rabbit anti-human p53
antibody CM-1 (Novocastra Laboratories, Newcastle upon
Tyne, UK) by using a dilution of 1:1000 (Soini et al., 1992).
This was followed by a biotinylated anti-rabbit immunoglo-
bulin (dilution 1:100, Dakopatts) and the avidin-biotin-
peroxidase complex (Dakopatts).
For proliferating cell nuclear antigen (PCNA) staining, a
mouse monoclonal IgG2a primary antibody was used (PC1O;
Dako). The sections were incubated with the primary
antibody (dilution 1:50) for 1 h followed by a secondary
rabbit anti-mouse antibody (1:200) (Dakopatts) and the
avidin-biotin-peroxidase complex (Dakopatts). Careful
rinses were done with several changes of PBS between each
stage of the procedure in all immunostainings.
For all the immunostainings, the colour was developed by
diaminobenzidine, whereafter the sections were lightly
counterstained with haematoxylin and mounted with Eukitt
(Kindler, Freiburg, Germany).
Negative control stainings were carried out by substituting
non-immune mouse or rabbit serum for the primary
antibodies. As a positive control for bcl-2 and PCNA
immunostaining, a lymph node with follicular hyperplasia
was used. As a positive control for p53 immunostaining, we
used sections from a lung carcinoma previously shown to be
strongly positive for p53 (Soini et al., 1992).
For bcl-2 and p53 stainings, the results were evaluated for
positive (+) or negative (-) staining. For PCNA, the
percentage of positively stained cells was evaluated in each
section. bcl-2 immunostaining appeared as cytoplasmic while
p53 and PCNA immunoreactivity was localised in the nuclei.
3'-End labelling of DNA in apoptotic cells
To identify apoptotic cells, in situ labelling of the 3' ends of
the DNA fragments generated by apoptosis-associated
endonuclease was used. The 3'-end labelling of DNA was
performed as previously described (T6rmanen et al., 1995).
For that purpose, the ApopTag in situ apoptosis detection kit
(Oncor, Gaithesburg, MD, USA), with a few modifications,
was used. The sections (one representative section per case)
were first dewaxed in xylene and rehydrated in alcohol, after
which they were incubated with 20 Mg ml-' Proteinase K
(Boehringer Mannheim, Mannheim, Germany) at room
temperature for 15 min. Endogenous peroxidase activity
was blocked by incubating the slides in 2% hydrogen
peroxide in PBS, pH 7.2. The slides were then treated with
terminal transferase enzyme and digoxigenin-labelled nucleo-
tides after which anti-digoxigenin-peroxidase solution was
applied on the slides. The colour was developed with
diaminobenzidine after which the slides were lightly counter-
stained with haematoxylin. For control purposes we used
tissue sections from hyperplastic lymph nodes showing an
increased number of apoptotic cells within germinal centers.
Assessment of apoptotic cells and apoptotic index
Cells were defined as apoptotic if the whole nuclear area of
the cell labelled positively (Figures 1 and 2). Apoptotic bodies
were defined as small positively labelled globular bodies in
the cytoplasm of the tumour cells that could be found either
singly or in groups (Figure 1). The apoptotic index was
defined as a sum of the apoptotic cells and bodies and it
reflected the total number of apoptotic events in a given area.
In cases in which many apoptotic bodies were found in a
group but clearly located in one cell, the group of apoptotic
bodies were counted as one (Figure 1). Apoptotic cells or
bodies were not evaluated from the vicinity of necrotic areas.
The number of apoptotic cells and bodies was counted in ten
a
b
Figure 1 (a) Strong apoptotic labelling can be seen in the
tumour cells of this HCC. Bar=200,um. (b) The same tumour
with a higher magnification. Three cells with apoptotic labelling
(arrowheads) and one cell with fragmented nuclear apoptotic
bodies (arrow) can be seen. Bar=20,um.PCNA, apoptosis and necrosis in hepatocellular carcinoma
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Tumour growth=cell production-cell loss
We designed a growth index for the tumours based on this
formula. For this, the values for positive staining for PCNA
as a measure of cell proliferation, apoptosis and necrosis as a
measure of cell death were projected on a semiquantitative
scale as follows:
PCNA index:
=0-25% of the cells positive;
2= 26-50% of cells positive;
3 = 51 -75% of cells positive;
4= 76-100% of cells positive.
Apoptotic index:
1 =0.00-0.50%;
2=0.51 - 1.10%;
3 = 1.1 1 -2.80%;
4= >2.80%.
Necrosis:
I1= <5%;
2=6-20%;
3 =21-40%;
4=41 -100%.
A combined index (growth index) was designed as follows;
Growth index=2 PCNA-(apoptosis score+necrosis score).
The indexes for each tumour obtained by this formula are
given in Table I.
Statistical analysis
Comparisons between groups were made using the two-tailed
Student's t-test. The significance of associations was
determined using Fisher's exact probability test and
correlation analysis.
The survival data were analysed according to the Kaplan-
Meier method. The difference between survival in different
groups was analysed using the log-rank, Breslow and
Tarone-Ware test. Probability values less than 0.05 were
considered significant.
Figure 2 (a) Weak apoptotic labelling can be seen in the tumour
cells of this HCC. Bar =200jpm. (b) The same tumor with a
higher magnification. One apoptotic cell (arrowhead) and one cell
with an apoptotic body (arrow) can be seen. Bar=20 jim.
high-power field (HPF) areas. The microscope used in all the
evaluations was Olympus System Microscope Model BHS-2
and the magnification used was 40 x . The diameter of the
field with this magnification is 400 gm. To estimate the
percentage of apoptotic events in a given area, i.e. the
apoptotic index, an approximate number of tumour cells in a
HPF area was calculated (mean 710, range 610 - 1210 cells
per HPF) and the number of apoptotic events in a field was
then divided by this figure and thus the percentage of
apoptotic events per cell population was obtained.
Mitoses and necrosis
Apart from staining for PCNA, cell proliferation was also
assessed by counting the number of mitotic figures per ten
HPFs. The extent of necrosis was assessed light micro-
scopically by evaluating the proportion of necrotic areas in
tumour tissue. The estimation of necrosis was performed
from on average five slides per case.
Determination of the growth index in tumours
According to Steel (1977), tumour growth can be given by a
simple equation where:
Results
PCNA, p53 and bcl-2 immunostainings
The results are compiled in Table I. 12/33 (36%) HCCs had a
high proliferation index (>50% of cells positive) as judged
by PCNA immunostaining (Figures 3 and 4). Positive nuclear
p53 immunostaining was found in 8/33 (23%) HCCs and
positive bcl-2 immunostaining only in 1/33 (3%) HCCs. In
non-neoplastic hepatocytes, no p53 staining and bcl-2
expression was found. bcl-2 expression was, however, found
in small proliferating bile ducts in association with cirrhosis
and portal inflammation. Interestingly, PCNA-positive non-
neoplastic hepatocytes were found in close proximity to the
tumour areas, suggesting increased proliferation in these
areas.
Apoptosis, mitosis and necrosis
The average relative number of apoptotic cells in HCCs was
0.28% (range 0.00-2.40%) and the average apoptotic index
(apoptotic cells and apoptotic bodies combined) 0.73%
(range 0.03-5.40%) (Figures 1 and 2). The average relative
number of apoptotic cells in non-neoplastic liver adjacent to
the tumours was 0.04% (range 0.00-0.10%) and the average
apoptotic index 0.10% (range 0.00-0.29%). As with PCNA
there were more apoptotic cells and bodies in immediate
proximity to the tumours. The average mitotic count in
a
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Table I Growth index, immunohistochemical expression of PCNA, apoptosis index, necrosis and immunohistochemical expression of p53 in
the HCCs analysed
Growth PCNA Apoptosis Necrosis Tumour
index (G) (%) (%) stage' p53
-3 5 0.51 40 T2NOMO -
-3 5 0.54 30 T3NOMO -
-1 10 0.44 20 T2NOMO -
-1 10 0.6 5 T2NOMO -
-1 20 0.51 0 T2NOMO -
-1 30 4.00 5 T3NOMO -
-1 40 3.00 0 T3NOMO -
0 5 0.42 5 T3NOMO -
0 5 0.30 5 T3NOMO -
0 5 0.1 0 T2NOMO -
0 5 0.37 0 T3NOMO -
0 10 0.02 0 T3NOMO -
0 20 0.4 5 TINOMO -
0 20 0.34 0 T2NOMO
0 30 0.27 30 T2NOMO +
0 30 0.28 35 T2NOMO -
0 40 0.2 30 T2NOMO -
0 40 0.17 25 T3NOMO -
0 40 0.21 40 T3NOMO -
0 70 1.28 40 T2NOMO -
0 95 5.4 50 T2NOMO +
+ 1 30 0.67 0 T2NOMO
+ 1 55 0.02 95 T2NOMO
+ 1 85 1.14 50 T2NOMO +
+ 2 40 0.45 0 T3NOMO
+2 70 0.30 30 T3NOMO
+3 70 0.41 15 T3NOMO
+ 3 70 0.05 20 T2NOMO +
+ 3 95 0.61 40 T2NOMO +
+4 65 0.18 5 T2NOMO
+4 70 0.28 5 T3NOMO +
+6 90 0.35 0 T3NOMO +
+6 95 0.17 0 T2NOMO +
Growth index calculated as follows: (PCNA score-Apoptosis score) + (PCNA score-Necrosis score). aAt the time of operation.
PCNA scores Apoptosis scores Necrosis scores
1= 0-25% positive 1= 0.00-0.50% labelled 1= <5% nercrosis
2= 26-50% positive 2= 0.51 -1.10% labelled 2= 6-20% nercosis
3= 51-75% positive 3= 1.11-2.80% labelled 3= 21-40% necrosis
4= 76-100% positive 4= >2.8% labelled 4= 41-100% nercosis
tumours was 11.7 per 10 HPFs (range 0.5-50.5) and the
average percentage of necrosis was 17.8% (range 0-95%).
Statistical analysis
There were significantly more cases with more than ten
mitoses per ten HPFs in the group with a high percentage of
PCNA positivity (>50% of cells positive) than in the group
with low PCNA positivity (<50% of cells positive) (P = 0.03,
Fisher's exact test). Similarly there was a positive correlation
between the percentage of PCNA-positive cells and the
frequency of mitoses (r = 0.524, P<0.05). There were
significantly more p53-positive cases in the group with a
high PCNA positivity (>50% of cells positive) than in the
group with low PCNA positivity (P=0.001, Fisher's exact
test). There were significantly more p53-positive cases with a
positive growth index than zero or a negative index
(P=0.015, Fisher's exact test). There were significantly more
relapses in cases with a positive growth index than in cases
with a zero or negative index (P=0.05, Fisher's exact test).
A strong positive correlation was found between the
frequency of apoptotic cells and apoptotic bodies (r=0.875,
P<0.001). No other significant associations were found
between any of the parameters.
Survival analysis
The survival analysis was performed against the following
variables; p53, PCNA, apoptotic index, necrosis, tumour size,
chemotherapy treatment, stage and growth index. There was
no significant difference in the patient survival between p53-
positive and -negative cases (P=0.33, log-rank), high (>50%
of cells positive) and low (<50% of cells positive) PCNA
index (P= 0.27, log-rank) high and low apoptotic index
(P=0.54, log-rank), high (>40%) or low (<40%) amount
of necrosis (P=0.52, log-rank) or large (> 10 cm) or small
(<10 cm) tumour size (P= 0.30, log-rank). Patients receiving
post-operative chemotherapy had a slightly shorter survival
than other patients (P=0.20, log-rank). The patients with
stage T3NOMO disease had a significantly shorter survival
than those with stage T2NOMO or TINOMO (P=0.005, log-
rank; P=0.0054, Breslow; P=0.002, Tarone-Ware). In
cases, in which the growth index was positive, the survival
of the patients was significantly shorter than in those in
which it was zero or negative (P=0.004, log-rank; P=0.006,
Breslow; P =0.004, Tarone-Ware) (Figure 5). Also the
disease-free interval after operation was significantly shorter
in patients with stage T3NOMO disease (P=0.014, log-rank;
P=0.034, Breslow; P =0.0022, Tarone-Ware) or positive
growth index (P=0.019, log-rank; P=0.0039, Breslow;
P=0.005, Tarone-Ware). There was no statistically sig-
nificant association between the growth index and TNM
status (P=0.82, Fisher's exact test).
Analysis of tumour growth in relapsing HCCs
In 11 patients, it was possible to follow the growth of a
relapsing tumour after the operation as in these patientsPCNA, apoptosis and necrosis in hepatocellular carcinoma
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control ultrasonography had been performed several times
after the operation and the sizes of the tumours were known.
In all these patients no tumour had been detected either by
the operating surgeon or by ultrasonography in the residual
liver immediately after surgery. In tumours with a positive
growth index, the relapsing tumour growth could be seen in
ultrasonography after 10.0+7.40 months, whereas in other
cases it appeared after 34.0+28.9 months. The growth rate of
the tumour in the former group was 0.42 cm+0.33 cm
month-', whereas in the latter group it was
0.16 cm+0.11 cm month
Discussion
This study was undertaken to analyse cell proliferation,
apoptosis and necrosis in HCC and their relationship to p53
and bcl-2 expression, survival and other clinical parameters
of the patients. To evaluate the growth potential of the
tumours, we scored them according to their proliferation
Figure 3 A HCC showing strong (+ + + +) st;
PCNA. Bar=200,m.
Figure 4 Another case showing weak (+) sta
PCNA. Bar= 200gim.
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Figure 5 A Kaplan-Meier survival curve showing
shorter survival in cases with a positive growth
cases with a growth index of zero or negative (
rank). Growth index: 0, positive (1-8); Ol, negat
aining for the index (as judged by PCNA immunostaining) subtracted by
the scores obtained for apoptosis and necrosis. The growth
index obtained this way was compared with patient survival
and other parameters. We found that patients whose tumours
showed a high degree ofproliferation relative to the degree of
necrosis and apoptosis (i.e. had a positive growth index) had
a significantly shorter survival and disease-free interval after
operation than patients whose tumours were predominated
by apoptosis or necrosis. When proliferation, apoptosis or
necrosis were considered separately, no statistically significant
association with the survival time or post-operative disease-
free interval was noticed. The results suggest that assessment
of growth potential by scoring for all the relevant parameters
(proliferation, apoptosis and necrosis) may be of value in
estimating patient prognosis. As these factors reflect the end
results of the genetic and associated biological changes in
tumours, their evaluation may be more practical than
analysing the expression of different oncogenes or tumour-
suppressor genes as several different cancer genes may be
affected in a single tumour and all of them cannot usually be
analysed at the same time.
Probably the best clinically observable correlate of the
growth index used in this study is the growth rate of the
tumour. Therefore we tested the growth rate and the
appearance of recurrent tumour in 11 tumours with
ultrasonographic data of tumour size measured on several
occasions. Tumours that had a positive growth index grew
lining for the three times faster and relapsed three times more quickly than
the others. This data then supports the fact that the growth
index is biologically relevant because it associates with the
ultrasonographically determined tumour growth data ob-
tained from the patients.
Survival and nost-onerative disease-free interval were also Jr
- r
-- _- -I- I11I- - -. -
strongly associated with the stage of the tumour. We did not,
however, find any association between the growth index and
the stage of the tumour, suggesting that these two variables
are independent of each other.
There are no previous reports on morphological analysis
on the extent and distribution of apoptosis in liver
carcinoma. The extent of apoptosis seems to vary in
different HCCs (see Table I). Generally, it is about the
same as we have recently noticed in non-small-cell lung
carcinoma, whereas small-cell lung carcinomas showed a
higher degree of apoptosis (T6rmanen et al., 1995). In non-
small-cell lung carcinoma, increased apoptosis was associated
with a shortened survival (T6rmanen et al., 1995), an
association which could not been found in HCCs, however.
100 120 Wild-type p53 has been shown to down-regulate the level
of bcl-2 and up-regulate bax gene expression (Miyashita et
al., 1994; Miyashita and Reed, 1995; Haldar et al., 1994).
;a significantly With a mutated, dysfunctional p53 gene, a decreased
index than in apoptosis could thus be expected. No significant association
P= 0.004, log- was found, however, between immunohistochemically detect-
ive (0 or less). able p53 expression and apoptosis. Our findings thus suggestPCVA. appdad necrosis in sp r
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that there are other factors that regulate the degree of
apoptosis in HCC. Candidates for such factors could be
other members of the bcl-2 family or the c-myc proto-
oncogene, which has been shown to induce apoptosis and is
probably able to up-regulate the bax gene (Miyashita and
Reed, 1995).
The frequency of p53 positivity in our material was about
the same as has been previously described in HCC in
European populations (Collier et al., 1994; Laurent-Puig et
al., 1992; Volkmann et al., 1994). p53 positivity in liver
tumours was associated with a high proliferation index and
also with a high growth index. This is as expected on the
basis of the central role of p53 in the regulation of cell
proliferation. Patients with p53-positive tumours had a
shorter survival than p53-negative ones, but the association
was not statistically significant.
We found only one HCC with an immunohistochemical
expression of bcl-2. This is in line with a previous study
showing no bcl-2 positivity in HCCs while considerable
positivity was found in cholangiocarcinomas (Charlotte et al.,
1994). Our results thus show that expression of bcl-2 in
HCCs is rare, but may occasionally be present. Interestingly,
proliferating bile epithelial cells associated with liver cirrhosis
or inflammation showed an increased expression of bcl-2.
Perhaps one associated mechanism for the increased number
of bile ductules in these conditions (in association with a
positive growth stimulus) is escape or protection of bile
ductular epithelial cells from apoptosis.
Interestingly, an increased number of apoptotic cells was
found among non-neoplastic hepatocytes adjacent to the
tumour. Similarly, PCNA-positive cells were found in these
areas. The finding suggests that tumour cells, perhaps
through production of cytokines or growth factors, might
stimulate apoptosis or cell proliferation in the adjacent non-
neoplastic hepatocytes.
In conclusion, our results show that the capacity of
tumour to grow (growth index as determined by PCNA,
apoptosis and necrosis scoring) is associated with a shortened
survival in operated HCCs. Evaluation ofthese parameters in
tumours may be of value in assessing the prognosis of the
disease.
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